To evaluate telomerase activity and proliferation of HS839.T melanoma cells, subjected to the action of AZT.
Introduction
Melanoma results from the uncontrolled proliferation of melanoblasts, of unknown etiology, and is one of the tumour with poorest prognosis. Several factors contribute to its arising, such as a genetic predisposition, exposure to sunlight, physical traumas to pre-existent nevi and immunodeficiencies. Melanoma accounts for 3 to 4% of all malignant skin tumour [1] [2] [3] [4] . Reports from various parts of the world have demonstrated an increase in its incidence and mortality rates 5, 6 .
Cancer cells present alterations in their nuclei, which usually occur in a single somatic cell that continues to divide until it forms a tumor. Its growth is fostered, among others, by angiogenic factors secreted by these cells, affecting even the maintenance of the DNA telomere size [7] [8] [9] .
Telomeres are specialized structures located at the ends of eukaryotic chromosomes, constituted of complex nucleoproteins and essential for the stability of the genome 10, 11 . Any telomere dysfunction contributes to reduce cell viability, altering the differentiation process 12, 13 .
The enzyme responsible for telomere synthesis is known as telomerase. It protects the ends of the DNA molecule against enzymatic degradation, preventing the occurrence of extremity fusions and warranting a correct duplication of the terminal regions of chromosomes, which may be necessary for the indefinite proliferation of human cells 11, 14 .
Telomerase activity is absent in the majority of human somatic cells but present in immortalized cell lines, stem and germ cells and in approximately 90% of human cancers 15 . There are studies suggesting that the progression of malignant diseases depends on telomerase reactivation, and that an inhibiting agent of this enzyme could be an effective antitumor drug 7, 15 .
Azidothymidine triphosphate (AZT) was shown in vitro to inhibit the action of telomerase in several tumour, with an important reduction of the telomeric terminals 10, [16] [17] [18] [19] .
The present study evaluated the telomerase activity and cell proliferation in HS839.T melanoma cells submitted to the action of AZT. 
Methods

Cell lines and cultures
Treatment of cells
After achieving 80% flask confluence, the cells were trypsinized (0.01%) (Sigma Aldrich, St Louis, MO, USA) and submitted to different AZT concentrations, with one control group without drug addition, followed by a group to which 50µM, 100µM and 200µM were added for 24 and 48 hours, respectively.
The experiments were carried out in triplicate.
Cell viability
MTT solution
In order to determine the metabolic activity and the degree of cell proliferation, 10 4 cells/well were distributed onto 96-well microplates with 100µL of DMEM medium, with the same supplementation. The plates were kept at 37°C with 5% CO 2 for 24 hours. Then the medium was aspired and replaced by fresh supplemented DMEM medium, simultaneously adding AZT at the defined concentrations for 24 and 48 hours, respectively. The cells were incubated again at 37ºC for 24 and 48 hours, respectively, then 10µl of MTT solution (5mg/ml) were added to each well, maintained for three hours, and then the medium was aspired and 100µl acidified isopropanol were added to each well for ten minutes, to dissolve the formazan crystals.
Analysis was performed with an ELISA plate reader (Labsystem Multiskan EX, Helsinki, Finland) at a wavelength of 450nm, with a reference filter of 590nm, and the metabolic activity was obtained by using its percentage in relation to the control.
Telomerase activity
Cell preparation for telomerase analysis The cell extracts were unfrozen and analyzed using the TRAPEZE ® RT kit.
The reaction mixture was then placed in an Eppendorf tube and taken to the thermocycler (Corbett Research Rotor Gene 3000, Sidney, Australia) for extension and amplification by polymerase chain reaction (PCR). Once the reaction was completed, the telomerase enzymatic expression was analyzed using real-time PCR.
To perform these experiments, a curve was constructed with standard protein (Figure 1 ), using 99% BSA (fraction V) (Sigma Aldrich, St Louis, MO, USA) and a protein assay kit (Biorad Laboratories, Hercules, CA, USA). 
Results
Cell viability
MTT solution
The results obtained for the enzymatic activity values in the cells of the 24-hours' treatment group are presented in Figure   2 . A gradual increase of the cell population was observed in all groups during the 24-hour period compared to the control group, with a tendency towards a decrease in enzymatic activity when 200µM of AZT were added. is shown in Figure 4 . A gradual increase in telomerase activity was observed in all groups during the 24-hour period compared to the control group, with a tendency towards a decrease in enzymatic activity when 200µM of AZT were added. Telomerase activity was evaluated with the Telomerase PCR-ELISA kit, both in the control and in the groups treated with
AZT. The distribution of the immunoabsorbance (OD) values
concerning telomerase activity is presented in Figure 5 . An initial decrease in telomerase activity was observed in the groups to which 50μM and 100μM of AZT had been added, after which there was a gradual increase compared to the control group, and no tendency towards a decrease in enzymatic activity was found with 200μM of AZT. 
TRAPEZE ® RT kit
Real-time polymerase chain reaction (RT-PCR) was performed using a TRAPEZE ® RT kit, both in the control and in the groups treated with AZT ( Figures 6 and 7) . A gradual increase in telomerase enzymatic activity was observed in all groups treated for 24 hours compared to the control group, and a tendency towards a decrease in enzymatic activity was found with 200μM
of AZT. RT-PCR was performed using a TRAPEZE ® RT kit, both in the control and in the groups treated with AZT (Figures 8 and   9 ). The primary theoretical reference in this study was qualitative, due to the fact that the sample was typically small, since we were looking for a cell behavior in front of a single bias, the different concentrations of AZT 22 .
Discussion
Melanoma develops from a malignant transformation of melanocytes, which undergo an uncontrolled growth and alterations in the nucleus 20, 21 .
There is strong evidence indicating an association between the maintenance of telomeres and the development of most of the various types of cancer in humans, including melanoma 22 .
Telomerase functions as a reverse transcriptase and its inhibiting agents are being tested, among them azidothymidine triphosphate, zidovudine (AZT), and it has been proven that in vitro this drug inhibits the action of telomerase 10, 16, [17] [18] [19] 23 .
The objective of the present study was to evaluate the activity of telomerase and the proliferation of immortalized The primary theoretical reference in this study was qualitative, due to the fact that the sample was typically small, since we were looking for a cell behavior in front of a single bias, the different concentrations of AZT 26 .
The evaluation of cell viability was performed according to the MTT technique 27 .
The AZT concentrations used were those most frequently mentioned in the literature 10, [16] [17] [18] , and we added them directly to the culture medium, respecting the 24 and 48-hours' time of action.
All the experiments were carried out in triplicate because this is the ideal in vitro study design, once cells of the same cell line carry the same genetic material, ruling out any other bias.
The tests showed a gradual increase of the cell population in all groups treated with AZT for 24 hours compared to the control groups, with a tendency to decrease at the 200µM concentration.
In the 48-hour groups, the same pattern was observed, but without the tendency to decrease at the dosage of 200µM.
Telomerase activity was evaluated in the cell groups treated with AZT for 24 and 48 hours and in the control groups, using the Telomerase PCR Elisa Kit, according to a previously described methodology 7 .
Telomerase activity was also measured using the Analyzing the results of the 48-hours' treatment, the same pattern was found, with an indication of a slight decrease in telomerase activity at the concentration of 50µM compared to the control group, although it was followed by a gradual increase in the activity of this enzyme, possibly related to the fact that the concentrations should have been higher, as suggested by Humer et al. 28 . Actually, our data corroborate the findings of Humer et al. 28 , who studied growth inhibition of melanoma cells in vivo and in vitro and observed that AZT concentrations below 200µM did not produce measurable cytotoxic effects on the cells, but with higher concentrations up to 500µM and a longer exposure time up to 72hours, the tested cells showed a substantial increase in apoptosis, indicating a dose-dependent relationship. These data suggest that the HS839.T melanoma cells used in the present study are sensitive to AZT, but regain their enzymatic and proliferation activity, with a possible neutralization of the reverse transcriptase inhibiting nucleoside originated from AZT.
In conclusion, the action of AZT in HS839.T melanoma cells at the concentrations and time periods tested did not inhibit telomerase activity, nor did it affect cell proliferation. However, based on our results and on the findings of Humer et al. 28 , we will conduct further experiments, performed with melanoma cells obtained by fine-needle aspiration puncture (FNAP), submitted to AZT treatment starting from 200 µM and with increasing doses and exposure of these cells to the drug for a period of time longer than 48 hours.
